BACKGROUND: Alterations in the metabolism of the amyloid precursor protein and the formation of beta-amyloid (Abeta) plaques are associated with neuronal death in Alzheimer disease (AD). The plaque subtype Abeta(x-42) occurs as an early event, with Abeta(x-40) plaques forming at a later stage. In dementia with Lewy bodies (DLB), an increase in the amount of cortical Abeta occurs without severe cortical neuronal losses. OBJECTIVE: To advance our understanding of the natural history of Abeta in neurodegenerative diseases. DESIGN: We evaluated the expression of Abeta(x-40) and Abeta(x-42) in DLB using monoclonal antibodies and immunohistochemical techniques in 5 brain regions. The data were compared with those elicited with normal aging and from patients with AD. SETTING AND PATIENTS: A postmortem study involving 19 patients with DLB without concurrent neuritic degeneration, 10 patients with AD, and 17 aged persons without dementia for control subjects. RESULTS: The Abeta plaques were more numerous in patients with DLB than in controls in most brain regions, although the Abeta(x-42) plaque subtype was predominant in both conditions. Overall, Abeta(x-42) plaque density was similar in patients with DLB and those with AD, but Abeta(x-40) plaques were more numerous in persons with AD than in those with DLB. The ratio of Abeta(x-40) to Abeta(x-42) plaques was significantly reduced in persons with DLB compared with patients with AD. CONCLUSIONS: The Abeta plaques were more numerous in patients with DLB than persons with normal aging, but the plaque subtypes were similar. The relative proportion of the 2 Abeta plaque subtypes in DLB is distinguishable from that in AD.
BACKGROUND: Alterations in the metabolism of the amyloid precursor protein and the formation of beta-amyloid (Abeta) plaques are associated with neuronal death in Alzheimer disease (AD). The plaque subtype Abeta(x-42) occurs as an early event, with Abeta(x-40) plaques forming at a later stage. In dementia with Lewy bodies (DLB), an increase in the amount of cortical Abeta occurs without severe cortical neuronal losses. OBJECTIVE: To advance our understanding of the natural history of Abeta in neurodegenerative diseases. DESIGN: We evaluated the expression of Abeta(x-40) and Abeta(x-42) in DLB using monoclonal antibodies and immunohistochemical techniques in 5 brain regions. The data were compared with those elicited with normal aging and from patients with AD. SETTING AND PATIENTS: A postmortem study involving 19 patients with DLB without concurrent neuritic degeneration, 10 patients with AD, and 17 aged persons without dementia for control subjects. RESULTS: The Abeta plaques were more numerous in patients with DLB than in controls in most brain regions, although the Abeta(x-42) plaque subtype was predominant in both conditions. Overall, Abeta(x-42) plaque density was similar in patients with DLB and those with AD, but Abeta(x-40) plaques were more numerous in persons with AD than in those with DLB. The ratio of Abeta(x-40) to Abeta(x-42) plaques was significantly reduced in persons with DLB compared with patients with AD. CONCLUSIONS: The Abeta plaques were more numerous in patients with DLB than persons with normal aging, but the plaque subtypes were similar. The relative proportion of the 2 Abeta plaque subtypes in DLB is distinguishable from that in AD.
Authors: Mei-Ping Kung; Daniel M Skovronsky; Catherine Hou; Zhi-Ping Zhuang; Tamar L Gur; Bin Zhang; John Q Trojanowski; Virginia M-Y Lee; Hank F Kung Journal: J Mol Neurosci Date: 2003-02 Impact factor: 3.444
Authors: Kazuchika Nishitsuji; Takami Tomiyama; Kenichi Ishibashi; Kazuhiro Ito; Rie Teraoka; Mary P Lambert; William L Klein; Hiroshi Mori Journal: Am J Pathol Date: 2009-01-22 Impact factor: 4.307
Authors: B Mollenhauer; M Bibl; H Esselmann; P Steinacker; C Trenkwalder; J Wiltfang; M Otto Journal: J Neural Transm (Vienna) Date: 2007-02-22 Impact factor: 3.850
Authors: Amani Alghamdi; Julie Vallortigara; David R Howlett; Martin Broadstock; Tibor Hortobágyi; Clive Ballard; Alan J Thomas; John T O'Brien; Dag Aarsland; Johannes Attems; Paul T Francis; David R Whitfield Journal: J Alzheimers Dis Date: 2017 Impact factor: 4.472
Authors: Zachary A Sorrentino; Marshall S Goodwin; Cara J Riffe; Jess-Karan S Dhillon; Yuxing Xia; Kimberly-Marie Gorion; Niran Vijayaraghavan; Karen N McFarland; Lawrence I Golbe; Anthony T Yachnis; Benoit I Giasson Journal: Acta Neuropathol Commun Date: 2019-09-02 Impact factor: 7.801
Authors: Jozef Hanes; Andrej Kovac; Hlin Kvartsberg; Eva Kontsekova; Lubica Fialova; Stanislav Katina; Branislav Kovacech; Eva Stevens; Jakub Hort; Martin Vyhnalek; Lynn Boonkamp; Michal Novak; Henrik Zetterberg; Oskar Hansson; Philip Scheltens; Kaj Blennow; Charlotte E Teunissen; Norbert Zilka Journal: Neurology Date: 2020-09-24 Impact factor: 9.910
Authors: David R Howlett; David Whitfield; Mary Johnson; Johannes Attems; John T O'Brien; Dag Aarsland; Mitchell K P Lai; Jasinda H Lee; Christopher Chen; Clive Ballard; Tibor Hortobágyi; Paul T Francis Journal: Brain Pathol Date: 2014-10-30 Impact factor: 6.508